Zevra Therapeutics, Inc. Accounts and Other Receivables, Net, Current
Zevra Therapeutics, Inc. (ZVRA) had Accounts and Other Receivables, Net, Current of $22.49 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:AccountsAndOtherReceivablesNetCurrent · last filed 2026-08-05
- 2026-06-30: Accounts and Other Receivables, Net, Current $22.49M.
- 2026-03-31: Accounts and Other Receivables, Net, Current $22.10M.
- 2025-12-31: Accounts and Other Receivables, Net, Current $23.26M.
- 2025-09-30: Accounts and Other Receivables, Net, Current $16.84M.
| Period end | Accounts and Other Receivables, Net, Current |
|---|---|
| 2026-06-30 | $22.49M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $22.10M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $23.26M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $16.84M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $18.27M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $12.62M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $10.51M 10-K · filed 2026-03-09 |
| 2024-09-30 | $7.79M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $8.95M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $8.30M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $17.38M 10-K · filed 2025-03-12 |
| 2023-09-30 | $9.93M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $14.03M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $7.82M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $8.30M 10-K · filed 2024-04-01 |
| 2022-09-30 | $6.58M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.82M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $3.32M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.53M 10-K · filed 2023-03-07 |
| 2021-09-30 | $1.62M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.89M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $11.31M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $2.58M 10-K · filed 2022-03-31 |
| 2020-09-30 | $2.20M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $2.09M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $2.27M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $1.86M 10-K · filed 2021-03-12 |
| 2019-09-30 | $1.64M 10-Q · filed 2019-11-14 |
| 2018-12-31 | $140.00K 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |